CJC-1295 (No DAC) + Ipamorelin (10 mg Blend) Dosage Protocol
This blend combines CJC-1295 (No DAC) — a modified GHRH analog — with Ipamorelin, a selective GH secretagogue. The two act on complementary receptor pathways to produce synergistic pulsatile growth hormone release: CJC-1295 amplifies GH pulse amplitude, while Ipamorelin triggers GH pulses through ghrelin receptor pathways without cortisol or ACTH elevation.
âš¡ Quickstart Highlights
Dosing & Reconstitution Guide
Standard / Gradual Approach (3 mL = 3.33 mg/mL total)
Route: Subcutaneous | Frequency: Once daily (typically before bed or upon waking)
| Week | Daily Dose (each peptide) | Total Blend | U-100 Units | Volume (mL) |
|---|---|---|---|---|
| Weeks 1–2 | 100 mcg each | 200 mcg | 3 units | 0.030 mL |
| Weeks 3–4 | 150 mcg each | 300 mcg | 4.5 units | 0.045 mL |
| Weeks 5–6 | 200 mcg each | 400 mcg | 6 units | 0.060 mL |
| Weeks 7–12 | 250–300 mcg each | 500–600 mcg | 7.5–9 units | 0.075–0.090 mL |
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water into a sterile syringe.
- Inject slowly down the inside glass wall of the blend vial; avoid foaming.
- Gently swirl or roll until dissolved. Do not shake.
- Label with the reconstitution date. Refrigerate at 2–8°C, protected from light. Use within ~28 days.
Supplies Planning
| Item | 8 Weeks | 12 Weeks | 16 Weeks |
|---|---|---|---|
| CJC-1295 + Ipamorelin blend vials (10 mg) | 3 vials | 4 vials | 5 vials |
| Insulin syringes (30- or 50-unit preferred) | 56 | 84 | 112 |
| Bacteriostatic water (10 mL) | 1 × 10 mL | 2 × 10 mL | 2 × 10 mL |
| Alcohol swabs | 2 × 100-pack | 2 × 100-pack | 3 × 100-pack |
How the Blend Works
CJC-1295 (No DAC) Mechanism
CJC-1295 (No DAC) is a modified GHRH (Growth Hormone-Releasing Hormone) analog — specifically a tetrasubstituted 29-amino acid peptide. It binds to GHRH receptors in the anterior pituitary and stimulates pulsatile GH secretion. Human studies demonstrate sustained, dose-dependent increases in both GH and IGF-1 with subcutaneous administration. The "no DAC" (no Drug Affinity Complex) version has a shorter half-life (~30 minutes) compared to the DAC version (~6–8 days), creating more physiologically natural GH pulses.
Ipamorelin Mechanism
Ipamorelin is a pentapeptide GH secretagogue (GHS) that mimics ghrelin and binds to the ghrelin receptor (GHSR-1a) in the pituitary gland. It has a half-life of approximately 1.5–2.5 hours and elicits a rapid GH pulse peaking around 40 minutes post-dose. Key advantage: Ipamorelin selectively increases GH without affecting ACTH, cortisol, or prolactin levels — making it more selective than older GHRPs like GHRP-2 and GHRP-6.
Synergistic Effect
CJC-1295 (No DAC) and Ipamorelin act through complementary receptor pathways. GHRH analogs amplify the amplitude of existing GH pulses, while ghrelin mimetics (GHRPs) trigger new GH pulses. Together they produce greater GH secretion than either alone — a well-documented synergy in GH secretagogue research.
Research Findings
- CJC-1295 (No DAC) demonstrated sustained, dose-dependent GH and IGF-1 increases in healthy adult humans in published trials.
- Ipamorelin was identified as the first highly selective growth hormone secretagogue — stimulating GH release without concomitant elevation of cortisol, ACTH, or prolactin.
- Once-daily CJC-1295 (No DAC) normalized growth in GHRH knockout mouse models.
- Generally well tolerated in research settings; possible transient effects may include flushing, water retention, headache, or tingling sensations.
- Some individuals report increased appetite — consistent with ghrelin receptor activation by Ipamorelin.
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months |
| Reconstituted | 2–8°C (35–46°F) | Up to 28 days; avoid freeze-thaw |